Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination analgesic regimen consisting of tramadol and oxycodone, currently being evaluated by the Mayo Clinic in a Phase 4 clinical trial (NCT07153003) for the management of postoperative pain following primary total knee arthroplasty (TKA) or total hip arthroplasty (THA). Tramadol is a synthetic opioid that provides analgesia through mu-opioid receptor agonism and the inhibition of serotonin and norepinephrine reuptake. Oxycodone is a semi-synthetic full mu-opioid receptor agonist. The study investigates whether this multimodal approach can improve pain control and reduce overall postoperative opioid consumption compared to oxycodone monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol + oxycodone.